OPEN LABEL RISPERIDONE IN CHILDREN AND ADOLESCENTS WITH AUTISTIC DISORDER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假设： 这项研究是一项多中心、开放标签的研究，旨在评估利培酮在减少符合DSM-IV和自闭症诊断访谈(ADI)标准的儿童和青少年表现出的易怒和相关行为方面的有效性。虽然行为和教育疗法以及各种药物可能有助于控制自闭症的某些症状，但目前还没有FDA批准的治疗方法。然而，非典型抗精神病药物已经成为治疗自闭症行为症状的有希望的疗法。利培酮是研究最严格的非典型抗精神病药物，它对自闭症患者的严重行为问题有效，因为它对多巴胺和5-羟色胺神经元系统有很强的影响，这两个系统都与自闭症的病理生理有关

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: This study is a multicenter, open-label study designed to assess the efficacy of risperidone in reducing irritability and associated behaviors displayed by children and adolescents who fulfill DSM-IV and Autism Diagnostic Interview (ADI) criteria. Although behavioral and educational therapies and a variety of medications may help manage some symptoms of autism, there are no FDA-approved treatments for the disorder. However, atypical antipsychotics have emerged as promising therapies for the behavioral symptoms of Autistic Disorder. Risperidone, the most rigorously studied of the atypical antipsychotics, is effective for serious behavioral problems in Autistic Disorder as it has potent effects on the dopamine and 5-HT neuronal systems, both of which have been implicated in the pathophysiology of autism